Brentuximab Vedotin (Adcetris®) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Collaborator
SGN35-013Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesNCT01461538Phase IISeattle Genetics
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaNCT01393717Phase IICity of Hope Medical Center, National Cancer Institute (NCI)
SGN35-012A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaNCT01421667Phase IISeattle Genetics, Inc
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNCT01805037Phase I, Phase IINorthwestern University and Seattle Genetics, Inc.
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)NCT01657331Phase I, Phase IIOwen A. O’Connor, British Columbia Cancer Agency, Princess Margaret Hospital, Canada and Columbia University
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)NCT01940796Phase IMassachusetts General Hospital, Seattle Genetics, Inc
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host DiseaseNCT01616680Withdrawn Phase IIFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, National Cancer Institute (NCI), Fred Hutchinson Cancer Research Center
Phase I/II – Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)NCT02096042Phase I, Phase IIM.D. Anderson Cancer Center, Seattle Genetics, Inc.
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaNCT01492088Phase I, Phase IIMillennium Pharmaceuticals, Inc
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaNCT01771107Phase I, Phase IINational Cancer Institute (NCI)
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationNCT01700751Phase 0Washington University School of Medicine
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaNCT01900496Phase 0Sidney Kimmel Comprehensive Cancer Center
A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin LymphomaNCT01990534Phase IVMillennium Pharmaceuticals, Inc.
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)NCT01026415Phase ISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin LymphomaNCT02298257Phase IIThe Lymphoma Academic Research Organisation
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsNCT01851200Phase IIFondazione Michelangelo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Millennium Pharmaceuticals, Inc.
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT02254239Phase IMayo Clinic, National Cancer Institute (NCI)
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin LymphomaNCT01780662Phase I, Phase IINational Cancer Institute (NCI)
Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT01896999Suspended Phase INational Cancer Institute (NCI)
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesNCT01620229Withdrawn Phase I, Phase IIFred Hutchinson Cancer Research Center, Seattle Genetics, Inc, National Cancer Institute (NCI)
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)NCT02169505Phase IIM.D. Anderson Cancer Center
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyNCT01671813WithdrawnH. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin’s Lymphoma PatientsNCT02164006Phase ITG Therapeutics, Inc.
ALCANZAA Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell LymphomaNCT01578499Phase IIIMillennium Pharmaceuticals, Inc, Seattle Genetics, Inc.
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaNCT02086604Phase IWashington University School of Medicine
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT02227199Phase I, Phase IIUniversity of Washington, National Cancer Institute (NCI)
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin LymphomaNCT01508312Phase IMemorial Sloan Kettering Cancer Center, Seattle Genetics, Inc.
Brentuximab Vedotin (Recombinant) for IV Infusion – Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma”NCT02139592Takeda
SGN35-015A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)NCT01716806Phase IIISeattle Genetics, Inc.
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaNCT01807598Jason Robert Gotlib, National Cancer Institute (NCI), Stanford University
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaNCT01920932Phase IISt. Jude Children’s Research Hospital|Seattle Genetics, Inc.
SGN35-016Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaNCT01874054Phase I |Phase IISeattle Genetics, Inc.
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaNCT01979536Phase INational Cancer Institute (NCI)
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT01902160Phase INational Cancer Institute (NCI)
To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell LymphomaNCT02280785Phase IISamsung Medical Center, Millennium Pharmaceuticals, Inc.
Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaNCT01909934Phase IVMillennium Pharmaceuticals, Inc.
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaNCT00365274Phase IINational Cancer Institute (NCI)
SGN35-017Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)NCT01925612Phase IISeattle Genetics, Inc.
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.NCT02227433Phase IIFondazione Italiana Linfomi ONLUS
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsNCT02280993Phase IIMarjolein Spiering, Millennium: The Takeda Oncology Company, Academisch Medisch Centrum (Universiteit van Amsterdam/AMC-UvA)
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin LymphomaNCT01060904Phase ISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30NCT01841021H. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc.
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaNCT01950364Phase IMillennium Pharmaceuticals, Inc
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsNCT01309789Phase ISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Evaluation Study of Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory HLNCT02243436Phase I |Phase IIGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin + Chemo for AMLNCT01830777Phase IMassachusetts General Hospital
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell LymphomaNCT00354107TerminatedNational Cancer Institute (NCI)
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin LymphomaNCT02166463Phase IIINational Cancer Institute (NCI)
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaNCT01578967UNC Lineberger Comprehensive Cancer Center, Seattle Genetics, Inc.
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaNCT02275598Phase II: University of Modena and Reggio Emilia, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDNCT02298283Phase IIThe Lymphoma Academic Research Organisation
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaNCT02191930Phase IIUniversity of Cologne (Germany)
Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ LymphomaNCT01703949University of Washington, National Cancer Institute (NCI)
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT00337194Phase IINational Cancer Institute (NCI)
ECHELON-2ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasNCT01777152Phase IIISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin for Steroid Refractory GvHDNCT01596218Phase IMassachusetts General Hospital, Seattle Genetics, Inc, Dana-Farber Cancer Institute
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin’s Lymphoma Patients Non Responding to IGEV Salvage TreatmentNCT02244021Phase IIFondazione Italiana Linfomi ONLUS
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaNCT01534078Phase IIMassachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc

SG035-0004

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaNCT00866047Phase IISeattle Genetics, Inc., Millennium Pharmaceuticals, Inc.
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell LymphomaNCT00099255Phase IISeattle Genetics, Inc.
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)NCT01026233Phase ISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaNCT01868451Memorial Sloan Kettering Cancer Center, Seattle Genetics, Inc, University of Rochester
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.NCT02292979Phase IIThe Lymphoma Academic Research Organisation, Millennium Pharmaceuticals, Inc.
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudyNCT00947856Phase IISeattle Genetics, Inc., Millennium Pharmaceuticals, Inc.

SG035-0003

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaNCT00848926Phase IISeattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression LevelNCT01396070Youn Kim, Seattle Genetics, Inc., Stanford University
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone LymphomasNCT01994850Phase I, Phase IIAbramson Cancer Center of the University of Pennsylvania
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma PatientsNCT02098512Phase I, Phase IINew York Medical College, St. Baldrick’s Foundation
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin LymphomaNCT01476410Phase IINorthwestern University, Robert H. Lurie Cancer Center, Seattle Genetics, Inc.
ECHELON-1Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin LymphomaNCT01712490Phase IIIMillennium Pharmaceuticals, Inc, Seattle Genetics, Inc.
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)NCT01352520Phase IIM.D. Anderson Cancer Center, Seattle Genetics, Inc.
AETHERASGN35-005A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)NCT01100502Phase IIISeattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesNCT00051597Phase I, Phase IISeattle Genetics, Inc
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaNCT00079755Phase IISeattle Genetics, Inc.
A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaNCT01196208Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaNCT01569204Phase IIUniversity of Cologne
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesNCT00649584Phase ISeattle Genetics, Inc
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesNCT00430846Phase ISeattle Genetics, Inc.

Last Editorial Review: August 11, 2015